The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size
Open accessAbstract
Conventional surgery and radiotherapy for acromegaly have limitations. There are few data on the use of the somatostatin analog octreotide (Oct) as primary medical therapy. An open prospective study of 27 patients with newly diagnosed acromegaly was conducted in nine endocrine centers in the United Kingdom. Twenty patients had macroadenomas, and 7 had microadenomas. For the first 24 wk (phase 1), patients received sc Oct in an initial dose of 100 microg, 3 times daily, increased to 200 micro g three times daily after 4 wk in the 13 patients whose mean serum GH remained greater than 5 mU/liter (2 microg/liter). Five-point GH profiles were performed at 0, 4, 12, and 24 wk, and high resolution pituitary imaging using a standard protocol was performed at 0, 12, and 24 wk (magnetic resonance imaging in 25 patients and computed tomography in 2). Tumor dimensions and volumes were calculated by a central, reporting neuroradiologist, and the results were audited by a second, independent neuroradiologist. After 24 wk, 15 patients proceeded to phase 2 of the study with a direct switch to monthly injections of the depot formulation of Oct, Sandostatin long-acting release (Oct-LAR). Further GH profiles were performed at 36 and 48 wk, and pituitary imaging was performed at 48 wk. The median pretreatment serum GH concentration was 30.7 mU/liter (range, 6.7-141.4). During sc Oct, serum GH fell to less than 5 mU/liter in 9 patients (38%), and IGF-I fell to normal in 8 patients (33%). All 27 tumors shrank during sc Oct; for microadenomas the median tumor volume reduction was 49% (range, 12-73), and for macroadenomas it was 43% (range, 6-92). After 24 wk of Oct-LAR (end of phase 2), the GH level was less than 5 mU/liter in 11 of 14 patients (79%), and IGF-I was normal in 8 of 15 patients (53%). In the 15 patients given Oct-LAR (10 macroadenomas), wk 48 scans showed a further overall median tumor volume reduction of 24%. At the end of the study 79% of patients had mean serum GH levels below 5 mU/liter, 53% had normal IGF-I levels, and 73% showed greater than 30% tumor shrinkage. Twenty-nine percent of patients achieved all 3 targets, but no patient with pretreatment GH levels above 50 mU/liter did so at any stage of the study. Primary medical therapy with Oct offers the prospect of normalization of GH/IGF-I levels together with substantial tumor shrinkage in a significant subset of acromegalic patients. This is most likely to occur in patients with pretreatment GH levels less than 50 mU/liter (20 microg/liter).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Self-citationMortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Dopamine Agonists and Pituitary Tumor Shrinkage
BEVAN, J. S., WEBSTER, J., Burke, C. W., & Scanlon, M. F. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-2-220 · Cited by 469
Self-citationLong-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly
Swearingen, B. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3419 · Cited by 400
Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience
Ahmed, Elsheikh, Stratton, Page, Adams, & Wass (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00760.x · Cited by 291
Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide
Vance, M. L. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400080073013 · Cited by 237
Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly
Colao, A., Ferone, D., Cappabianca, P., De, M. D. B., Marzullo, P., Monticelli, A., Alfieri, A., Merola, B., Calì, A., de Divitiis, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.10.3308 · Cited by 234
Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
Sheaves, R., Jenkins, P., Blackburn, P., Huneidi, A. H., Afshar, F., Medbak, S., Grossman, A. B., Besser, G. M., & Wass, J. A. H. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8370847.x · Cited by 199
Self-citationColao, A. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2779 · Cited by 179
SASSOLAS, G., Harris, A. G., James-Deidier, A., & THE FRENCH SMS 201–995≌ACROMEGALY STUDY GROUP† (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-391 · Cited by 136
Octreotide Long-Acting Release (LAR)
Gillis, J. C., Noble, S., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199753040-00009 · Cited by 125
Gallstones during octreotide therapy
Dowling, R. H., Hussaini, S. H., Murphy, G. M., BESSER, G. M., & Wass, J. A. H. (1992) · Metabolism · doi:10.1016/0026-0495(92)90027-8 · Cited by 102
Self-citationHow many surgeons to operate on acromegalic patients?
Clayton (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00711.x · Cited by 40
Current Therapy for Acromegaly
Stewart, P. M. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00244-7 · Cited by 39
Self-citationReevaluation of Conventional Pituitary Irradiation in the Therapy of Acromegaly
Jaffe, C. A. (1999) · Pituitary · doi:10.1023/a:1009969921497 · Cited by 29
Cited by
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
Acromegaly pathogenesis and treatment
Melmed, S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39375 · Cited by 687
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’
Nomikos, P., Buchfelder, M., & Fahlbusch, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01863 · Cited by 500
Mechanisms for pituitary tumorigenesis: the plastic pituitary
Melmed, S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320401 · Cited by 456
Metadata
- Authors
- Bevan, J. S., Atkin, S. L., Atkinson, A. B., Bouloux, P.-M., Hanna, F., Harris, P. E., James, R. A., McConnell, M., Roberts, G. A., Scanlon, M. F., Stewart, P. M., Teasdale, E., Turner, H. E., Wass, J. A. H., & Wardlaw, J. M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-10-01
- Volume
- 87
- Issue
- 10
- Pages
- 4554-4563
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2111216596
- Cited by
- 279
- References
- 16
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.